Compare BYND & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | IKT |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.6M | 220.5M |
| IPO Year | 2018 | 2020 |
| Metric | BYND | IKT |
|---|---|---|
| Price | $11.51 | $2.31 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $0.83 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 950.3K | 355.2K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.69 | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $275,496,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $1.33 |
| 52 Week High | $15.47 | $2.61 |
| Indicator | BYND | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 46.75 |
| Support Level | $0.65 | $2.29 |
| Resistance Level | $15.47 | $2.31 |
| Average True Range (ATR) | 0.77 | 0.10 |
| MACD | -0.36 | -0.02 |
| Stochastic Oscillator | 62.09 | 26.51 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.